US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2019-04-30
DOI
10.1080/09546634.2019.1603361
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
- (2018) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
- (2018) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
- (2018) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
- (2018) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
- (2018) Jaime Notario et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience
- (2017) Mami Momose et al. JOURNAL OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study
- (2017) A. Körber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study
- (2017) J.R. Georgakopoulos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
- (2015) Ian Landells et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
- (2014) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
- (2008) Amy S. Paller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search